VRTX - Proteostasis Recruits Patients Quicker Than Anticipated Results From CF Studies Now Expected Q4 2019
Proteostasis Therapeutics (PTI) is a biotech that should be on everyone's radar. That's because there are a few catalysts that are approaching in Q4 of 2019. Phase 1 results were released for PTI's doublet and triplet combination back in March of 2019. Investors put emphasis and focus on the triplet data from Proteostasis data. That's especially true because Vertex Pharmaceuticals (VRTX) just recently received FDA approval for its triplet combination for Cystic Fibrosis ((CF)) known as Trikafta. Most investors have brushed off Proteostasis, because of the 14-day doublet and triplet data, but as